Livmarli® (maralixibat) – New formulation approval
April 14, 2025 - Mirum Pharmaceuticals announced the FDA approval of Livmarli (maralixibat) tablets, for the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome; and cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis.
Top